Helicobacter pylori eradication: an up-to-date

Tom�s Navarro-Rodriguez; Ivanna Beserra Santos; Ricardo Corr�a Barbuti; Jaime Natan Eisig

Volume : IV, Issue : X, October - 2015

Helicobacter pylori eradication: an up-to-date

Tom S Navarro Rodriguez, Ivanna Beserra Santos, Ricardo Corr A Barbuti, Jaime Natan Eisig

Abstract :

Helicobacter pylori (H pylori) is a gram negative, non-spore forming spiral the bacterium which colonizes the human stomach. This microorganism is not a commensally one, so the infection always causes gastric mucosal inflammation and damage. H. pylori has been detected in individuals of all ages throughout the world and its prevalence ranges between 20%-80%. H. pylori-related gastric diseases create a heavy burden on health care systems world-wide. In the current progress report, it has been described in a practical way, its several therapeutic treatment approaches. The eradication of H. pylori is not simple and the therapeutic schemes demand a combination of multiple pharmacological agents. Some schemes that have excellent eradication rates in developed countries do not show the same results in developing countries, and vice versa. These differences are secondary to primary antibiotic resistance of the bacterium. Despite the use of various treatment regimens, around 20% of patients remain infected and need retreatment under different therapeutic schemes. These rescue antibiotic combinations also vary a lot among countries, since there are again, different resistance profiles, as well as, different antimicrobials availability.